Remedent Reports Fourth Quarter and Year End Results and Remedent to Host a Conference Call at 11:00 A.M. EST, Tuesday, July 20,

  Remedent, Inc. (OTCBB: REMI), an
international company specializing in research, development, and
manufacturing of oral care and cosmetic dentistry products, reported
results for the final quarter and for the year ended March 31, 2010 (in US
Dollars).

Net sales in the fourth quarter decreased 27% to $2.5 million from $3.4 million in the same year ago quarter. The decrease in sales was due to non recurring license fees of approx $1 million received from Denmat in the fourth quarter ended March 31, 2009.

Loss from operations in the fourth quarter was a loss of $111,138 $(0.01) per share as opposed to a loss of $1,079,063 $(0.05) in the same year-ago quarter, based upon 20 million weighted average basic shares outstanding.

Net loss for the year ended March 31, 2010 was $2.4 million or $(0.12) per share, as compared with a loss of $3.0 million or $(0.15) per share for the year ended March 31, 2009.

Cash and cash equivalents totaled $614,000 at March 31, 2010 as opposed to $1.8 million at March 31, 2009.

Management Commentary

"Our sales strategy of shifting from our previous wholesale sales (B2B) model via a distributor to a direct retail model (B2C) is beginning to take shape. Included in our net loss of $111,000 for the fourth and final quarter ended March 31, 2010, was a loss of $550,000 directly attributable to our subsidiary Sylphar. The improved results are attributable to the inclusion for the first time of our Asian operations into our consolidated financial statements together with the gain realized from the sale of First Fit. Sales at all our Spa locations, namely in Beijing, Hong Kong, Taiwan and in Europe continue to exceed our expectations as sales continue to climb during the first quarter of the next financial year," said Guy De Vresse the CEO of Remedent.

Conference Call Information

Remedent will host a conference call on July 20, 2010 at 11:00 a.m. Eastern Standard time (8:00 a.m. Pacific time) to discuss these results and its strategic plans for the future. A question and answer session will follow management's presentation. To participate in the call, dial the appropriate number 5-10 minutes prior to the start time.

Date: Tuesday,  July 20,2010
Time 11:00 a.m. Eastern time (8:00 a.m. Pacific time).
Dial in number: 1-888-677-8749
International: 1-913-312-1482

A simultaneous web cast and replay of the call will be available through July 31, 2010. The replay pass code is 8101477.

About Remedent

Remedent, Inc. specializes in the research, development, manufacturing and marketing of oral care and cosmetic dentistry products. The company serves professional dental industry with breakthrough technology for dental veneers. These products are supported by a line of professional veneer whitening and teeth sensitivity solutions. Headquartered in Belgium, Remedent distributes its products to more than 35 countries worldwide. For more information, go to www.remedent.com.

Statement under the Private Securities Litigation Reform Act of 1995

Statements in this press release that are "forward-looking statements" are based on current expectations and assumptions that are subject to risks and uncertainties. Such forward-looking statements involve known and unknown risks, uncertainties and other unknown factors that could cause Remedent's actual operating results to be materially different from any historical results or from any future results expressed or implied by such forward-looking statements. In addition to statements that explicitly describe these risks and uncertainties, readers are urged to consider statements that contain terms such as "believes," "belief," "expects," "expect," "intends," "intend," "anticipate," "anticipates," "plans," "plan," "projects," "project," to be uncertain and forward-looking. Actual results could differ materially because of factors such as Remedent's ability to achieve the synergies and value creation contemplated by the proposed transaction. For further information regarding risks and uncertainties associated with Remedent's business, please refer to the risk factors described in Remedent's filings with the Securities and Exchange Commission, including, but not limited to, its annual report on Form 10-K and quarterly reports on Form 10-Q.

                      REMEDENT, INC. AND SUBSIDIARIES
                  CONSOLIDATED STATEMENTS OF OPERATIONS
                                (unaudited)



                           Three months ended            Year ended
                                March 31,                 March 31,
                            2010         2009         2010         2009
                        -----------  -----------  -----------  -----------
Net sales               $ 2,472,815  $ 3,390,355  $ 8,247,940  $14,639,541
Cost of sales               952,189    1,650,315    4,322,680    6,614,723
                        -----------  -----------  -----------  -----------
  Gross profit            1,520,626    1,740,040    3,925,260    8,024,818
                        -----------  -----------  -----------  -----------
Operating Expenses
Research and development     39,850       24,273      271,195      248,652
Sales and marketing         461,078      370,042    1,352,260    2,793,970
General and
 administrative           1,313,812    1,639,656    4,524,324    5,312,192
Depreciation and
 amortization               168,218      173,903      726,499      615,674
                        -----------  -----------  -----------  -----------
TOTAL OPERATING
 EXPENSES                 1,982,958    2,207,874    6,874,278    8,970,488
                        -----------  -----------  -----------  -----------
  OPERATING LOSS           (462,332)    (467,834)  (2,949,018)    (945,670)
                        -----------  -----------  -----------  -----------
NON-OPERATING (EXPENSE)
 INCOME
Warrants issued pursuant
 to Distribution Agreement       --           --     (168,238)  (4,323,207)
Gain on disposition of OTC       --           --           --    2,830,953
IMDS provision                   --     (300,000)          --     (300,000)
Interest expense/other
 deductions                 (50,596)    (166,972)    (171,364)    (417,147)
Interest income/other
 income                      54,907        1,884      170,244      348,997
Other income                     --           --     (169,358)          --
                        -----------  -----------  -----------  -----------
TOTAL OTHER INCOME
 (EXPENSES)                   4,311     (465,088)    (168,238)  (1,860,404)
                        -----------  -----------  -----------  -----------

LOSS FROM CONTINUING
 OPERATIONS BEFORE
 INCOME TAXES              (458,021)    (932,922)  (3,118,376)  (2,806,074)
Income tax expense          (14,242)     (32,633)     (14,242)     (32,633)
                        -----------  -----------  -----------  -----------

NET LOSS FROM CONTINUING
 OPERATIONS BEFORE
 MINORITY INTEREST         (472,263)    (965,555)  (3,132,618)  (2,838,707)
NET (LOSS) INCOME
 ATTRIBUTABLE TO
 NON-CONTROLLING
 INTERESTS                 (346,683)     114,208     (782,703)     114,208
                        -----------  -----------  -----------  -----------

NET LOSS FROM CONTINUING
 OPERATIONS, ATTRIBUTABLE
 TO REMEDENT INC. COMMON
 STOCKHOLDERS           $  (111,138) $(1,079,763) $(2,349,915) $(2,952,915)
                        ===========  ===========  ===========  ===========

LOSS PER SHARE
Basic and fully diluted $     (0.01) $     (0.06) $     (0.12) $     (0.15)
                        ===========  ===========  ===========  ===========
WEIGHTED AVERAGE
 SHARES OUTSTANDING
Basic and fully
 diluted                 19,995,969   19,995,969   19,995,969   19,559,653
                        ===========  ===========  ===========  ===========

OTHER COMPREHENSIVE
 INCOME (LOSS):
Net loss attributable
 to Remedent, Inc.
 common stockholders    $  (111,138) $(1,079,763) $(2,349,915) $(2,952,915)
Foreign currency
 translation adjustment    (102,949)     (45,371)      (9,464)    (668,245)
                        -----------  -----------  -----------  -----------
Total other comprehensive
 loss                      (214,287)  (1,125,134)  (2,359,379)  (3,621,160)
Less: comprehensive
 (loss) income
 attributable to
 non-controlling
 interest                   (42,623)     (54,700)       7,130      (54,700)
                        -----------  -----------  -----------  -----------
COMPREHENSIVE LOSS
 ATTRIBUTABLE TO
 REMEDENT INC.,
 COMMON STOCKHOLDERS    $  (171,664) $(1,070,434) $(2,366,509) $(3,566,460)
                        ===========  ===========  ===========  ===========




                      REMEDENT, INC. AND SUBSIDIARIES
                        CONSOLIDATED BALANCE SHEETS


                                              March 31,2010  March 31,2009
                                              -------------  -------------
ASSETS
CURRENT ASSETS:
Cash and cash equivalents                     $     613,466  $   1,807,271
Accounts receivable, net of allowance for
 doubtful accounts of $65,845 at March 31,
 2010 and $33,966 at March 31, 2009                 806,931      3,208,120
Inventories, net                                  2,161,692      1,937,946
Prepaid expense                                     920,487      1,310,900
                                              -------------  -------------
Total current assets                              4,502,576      8,264,237
                                              -------------  -------------
PROPERTY AND EQUIPMENT, NET                       1,735,719      1,024,999
OTHER ASSETS
Long term investments and advances                  750,000        750,000
Patents, net                                        246,992        163,106
Goodwill                                            699,635             --
                                              -------------  -------------
Total assets                                  $   7,934,922  $  10,202,342
                                              =============  =============
LIABILITIES AND STOCKHOLDERS' EQUITY
 (DEFICIT)
CURRENT LIABILITIES:
Current portion, long term debt               $     215,489  $      78,798
Line of Credit                                      674,600        660,200
Accounts payable                                  1,932,684      1,398,420
Accrued liabilities                                 491,536      1,590,360
Due to related parties                              268,484             --
Income taxes payable                                     --         39,339
                                              -------------  -------------
Total current liabilities                         3,582,793      3,767,117
  Long term debt less current portion               425,882        100,542
                                              -------------  -------------
Total liabilities                                 4,008,675      3,867,659
                                              -------------  -------------

EQUITY:
Preferred Stock $0.001 par value (10,000,000
 shares authorized, none issued and
 outstanding)                                           --            --
Common stock, $0.001 par value; (50,000,000
 shares authorized, 19,995,969 shares issued
 and outstanding at March 31, 2010 and
 19,995,969 shares issued and outstanding at
 March 31, 2009)                                     19,996         19,996
Treasury stock, at cost; 723,000 and 723,000
 shares at March 31, 2010 and March 31, 2009
 respectively                                      (831,450)      (831,450)
  Additional paid-in capital                     24,742,201     24,106,055
Accumulated deficit                             (19,565,943)   (17,216,028)
Accumulated other comprehensive income (loss)
 (foreign currency translation adjustment)         (650,059)      (640,595)
Obligation to issue shares                           97,500             --
                                              -------------  -------------
Total Remedent, Inc. stockholders' equity         3,812,245      5,437,978
                                              -------------  -------------
Non-controlling interest                            114,002        896,705
                                              -------------  -------------
Total stockholders' equity                        3,926,247      6,334,683
                                              -------------  -------------
Total liabilities and equity                  $   7,934,922  $  10,202,342
                                              =============  =============

Stephen Ross 310-922-5685 [e-mail]